Hematocrit, Phlebotomy Benefits Seen With Rusfertide in PV

No new safety concerns emerged in the 20-week extension of the phase 3 VERIFY study.
Medscape Medical News

source https://www.medscape.com/viewarticle/hematocrit-phlebotomy-benefits-seen-rusfertide-pv-2025a1000y84?src=rss